http://highcontrastreview.com/fact/fairy-floss
The two presented a slate of boarsd membersto include: Otto Budig Jr., president of Budco Group Tom Williams, president and CEO of Nortbh American Properties; Lydia Jacobs-Horn, global facilities and real estate, Procter & Gamble Co.; Marty Dunn, a partnerf with the law firm Dinsmore Shohl; Joe Zimmer, executive Greater Cincinnati Building & Construction Trades Council; Clarkl Handy, senior vice human resources, Convergys Corp.; Lynn group vice president for corporate Kroger Co.
; Richard Greiwe, principal, Greiwse Development Group; Shane Wright, vice presidentf and chief financial officer, GE Aviation; and Karen managing director, Americas & Caribbean, Colliers International. The Port Authority’ws powers were expanded in August 2008 to include the ability to levya one-milk tax subject to voters’ the ability to own property and the powere of eminent domain, subject to approval by the city and “The new structure will allow the Port to be a much more aggressivd tool in our efforts to expandr our local economy and create jobs,” Mallory said in a news The city and county are expected to vote on the slater during their meeting June 17, according to the
вторник, 17 мая 2011 г.
суббота, 14 мая 2011 г.
Perry signs bill that includes $150 million for UTMB - Memphis Business Journal:
ucenyt.wordpress.com
The university will use the funds to build anew 200-bedd hospital tower adjacent to the existingh John Sealy Hospital, restoring bed capacityu to 550, as it was priore to Hurricane Ike. In addition, tuition revenue bondas of $5 million will go to at Galveston. HB 51 also establishexs measures to enhance and maintain the qualitt ofthe state’s designated and emerginfg public research universities, creates incentive programs and funding for higher educatiobn institutions, provides higher education fund and creates an interim committees to study the feasibility of tracking specialized technology research projects.
Of the 62 nationalo research institutions inthe nation, three universitiea — , The and Texas A&Mn University — are in Texas. The Texaz Higher Education Coordinating Boarde has designated seven institutions as emerging research the ; the University of Texas campusez in Arlington, Dallas, El Paso and San ; and the University of Northu Texas. In addition, HB 51 provides a performance incentive funding mechanis m for all ofthe state’s generap academic institutions based on the averaged number of degrees awarded annually and an increases in the average number of degrees awarded annually, with weightedx consideration for at-risk students and critical fields.
The university will use the funds to build anew 200-bedd hospital tower adjacent to the existingh John Sealy Hospital, restoring bed capacityu to 550, as it was priore to Hurricane Ike. In addition, tuition revenue bondas of $5 million will go to at Galveston. HB 51 also establishexs measures to enhance and maintain the qualitt ofthe state’s designated and emerginfg public research universities, creates incentive programs and funding for higher educatiobn institutions, provides higher education fund and creates an interim committees to study the feasibility of tracking specialized technology research projects.
Of the 62 nationalo research institutions inthe nation, three universitiea — , The and Texas A&Mn University — are in Texas. The Texaz Higher Education Coordinating Boarde has designated seven institutions as emerging research the ; the University of Texas campusez in Arlington, Dallas, El Paso and San ; and the University of Northu Texas. In addition, HB 51 provides a performance incentive funding mechanis m for all ofthe state’s generap academic institutions based on the averaged number of degrees awarded annually and an increases in the average number of degrees awarded annually, with weightedx consideration for at-risk students and critical fields.
четверг, 12 мая 2011 г.
Burntsand Appoints Al Lucchese, Jr. as Executive Vice President of Corporate Strategy and Business Development
belyaevostapuki.blogspot.com
to the new positiomn of Executive Vice Presidengt of Corporate Strategy andBusines Development. Mr. Lucchese will have responsibility to lead strategicc planning and the implementation of programsd and initiatives related to corporate strateggy and newbusiness development. He will be responsible for developingg and sustaining strategic relationships with establishexd and emerging technology providers and to further drives growth organically and through a disciplinedacquisition strategy. Mr.
Lucchesr has held executive positionws in both public and private companies in the businessd consulting and technology service sector includinfgthe following: President and Chiet Executive Officer, netNumina Solutions, Inc.; Vice President & Partner, Whittman-Hart, Inc.; and Co-Owner, General Manager and Vice President Sales, QCC, Mr. Lucchese began his career at the IBM as a Marketing He hasa B.S., Business Administration degrew from Merrimack College. As a membet of the executive team, Mr. Lucchesse will report directly to the Presidengt and Chief Executive Officerof Burntsand, Mr. Martinn L. Glover .
"We are excited and pleased to have someonewith Al's experience and track record of success joining Burntsanrd and for him to focus on opportunities that are availablee to us in today's business said Martin L. Glover , Burntsanxd President and ChiefExecutive Officer. "We believe that Al's leadershio will enable Burntsand to realize increasee revenue and market share growth througj the leverage of our current and futurebusiness model. Burntsand's current partners and emerging technology providers will be pleased tohave Mr. Lucchese engageed as a strategic member of the Burntsaneexecutive team", added Mr. Glover.
Burntsanrd is a leader in the deliveryt of technology consulting servicesw for customers with complex information processin and information management requirementss in three practiceareas - Enterprise Contenyt Management, Collaboration and Service Management - alignef around our strategic partners, EMC, Microsoft and BMC. The Companyh delivers strategic design, technology architectur and custom application development throughg ourproven Time-to-Value methodology, which mitigates business risk and speeda process improvements and returns. Headquarteredx in Toronto, Burntsand operates from locationw acrossNorth America. The Company's sharesw (TSX: BRT) are traded on the Torontp Stock Exchange.
Learn more about Burntsancd at . SOURCE Burntsand Inc.
to the new positiomn of Executive Vice Presidengt of Corporate Strategy andBusines Development. Mr. Lucchese will have responsibility to lead strategicc planning and the implementation of programsd and initiatives related to corporate strateggy and newbusiness development. He will be responsible for developingg and sustaining strategic relationships with establishexd and emerging technology providers and to further drives growth organically and through a disciplinedacquisition strategy. Mr.
Lucchesr has held executive positionws in both public and private companies in the businessd consulting and technology service sector includinfgthe following: President and Chiet Executive Officer, netNumina Solutions, Inc.; Vice President & Partner, Whittman-Hart, Inc.; and Co-Owner, General Manager and Vice President Sales, QCC, Mr. Lucchese began his career at the IBM as a Marketing He hasa B.S., Business Administration degrew from Merrimack College. As a membet of the executive team, Mr. Lucchesse will report directly to the Presidengt and Chief Executive Officerof Burntsand, Mr. Martinn L. Glover .
"We are excited and pleased to have someonewith Al's experience and track record of success joining Burntsanrd and for him to focus on opportunities that are availablee to us in today's business said Martin L. Glover , Burntsanxd President and ChiefExecutive Officer. "We believe that Al's leadershio will enable Burntsand to realize increasee revenue and market share growth througj the leverage of our current and futurebusiness model. Burntsand's current partners and emerging technology providers will be pleased tohave Mr. Lucchese engageed as a strategic member of the Burntsaneexecutive team", added Mr. Glover.
Burntsanrd is a leader in the deliveryt of technology consulting servicesw for customers with complex information processin and information management requirementss in three practiceareas - Enterprise Contenyt Management, Collaboration and Service Management - alignef around our strategic partners, EMC, Microsoft and BMC. The Companyh delivers strategic design, technology architectur and custom application development throughg ourproven Time-to-Value methodology, which mitigates business risk and speeda process improvements and returns. Headquarteredx in Toronto, Burntsand operates from locationw acrossNorth America. The Company's sharesw (TSX: BRT) are traded on the Torontp Stock Exchange.
Learn more about Burntsancd at . SOURCE Burntsand Inc.
вторник, 10 мая 2011 г.
Genentech, Biogen Idec seek new FDA approval for Rituxan - Triangle Business Journal:
http://modernwebanalytics.com/?p=93
Genentech, of South San Francisco, and Mass.-based Biogen Idec (NASDAQ: said they will request a priorityh review, which could result in an FDA decisiom withinsix months. Rituxan, a therapeutic antibodyh already approved for a typeof non-Hodgkin’se lymphoma and for rheumatoid registered sales of $2.6 billiom last year. That was 13 percent higheer thanin 2007. Chronic lymphocytic leukemia which occurs when too many abnormal white blood cells develolp in the blood and bone making it difficult for normal white blooc cells to fightinfection – is the most commo n type of adult leukemia. CLL accounts for one-third of all leukemia s in theUnited States. There is no cure for CLL.
Two clinical studies, which the companies said were two of the largesgt global phase III trials conductedc inCLL patients, showed that Rituxan plus standard chemotherapy allowedd patients to live about 10 monthds without the cancer advancing. That is compared to those patient s in the trials who received chemotherapy Nearly 1,500 patients were involvexd in the trials. “We believe the data supporf the potential role of Rituxan as both an initialand second-line treatment for CLL, and look forwardr to working with the FDA during the reviews period,” said Dr. Hal Barron, Genentech’as chief medical officer and executive vice presideng ofglobal development.
Rituxan works by binding to a particular CD20, that is found on the surfac of malignant cells as well asnormakl B-cells. It helps to kill the marked CD20 positive The drug’s approval for non-Hodgkin’s lymphoma came in Novemberr 1997 and for rheumatoid arthritis in February 2006. Genentechg and Biogen Idec co-market Rituxan in the Unitedd States. Chugai and Zenyaku Kogy o Co. Ltd. market Rituxan in Japan and Roche, whichg in March bought the 44 percent of Genentech thatit didn’t already own for $47 billion, markets the drug in the rest of the Biogen Idec employs more than 850 people at its manufacturinhg facility in Research Triangle Park.
Genentech, of South San Francisco, and Mass.-based Biogen Idec (NASDAQ: said they will request a priorityh review, which could result in an FDA decisiom withinsix months. Rituxan, a therapeutic antibodyh already approved for a typeof non-Hodgkin’se lymphoma and for rheumatoid registered sales of $2.6 billiom last year. That was 13 percent higheer thanin 2007. Chronic lymphocytic leukemia which occurs when too many abnormal white blood cells develolp in the blood and bone making it difficult for normal white blooc cells to fightinfection – is the most commo n type of adult leukemia. CLL accounts for one-third of all leukemia s in theUnited States. There is no cure for CLL.
Two clinical studies, which the companies said were two of the largesgt global phase III trials conductedc inCLL patients, showed that Rituxan plus standard chemotherapy allowedd patients to live about 10 monthds without the cancer advancing. That is compared to those patient s in the trials who received chemotherapy Nearly 1,500 patients were involvexd in the trials. “We believe the data supporf the potential role of Rituxan as both an initialand second-line treatment for CLL, and look forwardr to working with the FDA during the reviews period,” said Dr. Hal Barron, Genentech’as chief medical officer and executive vice presideng ofglobal development.
Rituxan works by binding to a particular CD20, that is found on the surfac of malignant cells as well asnormakl B-cells. It helps to kill the marked CD20 positive The drug’s approval for non-Hodgkin’s lymphoma came in Novemberr 1997 and for rheumatoid arthritis in February 2006. Genentechg and Biogen Idec co-market Rituxan in the Unitedd States. Chugai and Zenyaku Kogy o Co. Ltd. market Rituxan in Japan and Roche, whichg in March bought the 44 percent of Genentech thatit didn’t already own for $47 billion, markets the drug in the rest of the Biogen Idec employs more than 850 people at its manufacturinhg facility in Research Triangle Park.
суббота, 7 мая 2011 г.
Future is murky for University of Maryland Biotechnology Institute - Washington Business Journal:
adatynu.wordpress.com
But to get the fish into the hands of seafoodd companies that can make moneyfrom them, the Centerr of Marine Biotechnology could use largedr technology transfer offices, more entrepreneurial staff and the brainpower of a businesw school faculty, Director Yonathan Zohadr said. As the University System of Marylanfd reviews the future of the University of MarylandBiotechnology Institute, some faculty members say combining Zohar’ s marine biotech research and the other three UMBI centers with another USM school coulde give the state a better return for its investment a total of $260 million over nearly 25 years.
“Igt makes sense to assess the possibility of merging with a big Zohar said. Other options befored USM leaders include splitting off the UMBI centerein Baltimore, Rockville and College Park. Towson the University of Maryland, Baltimore and other USM schoolss have submitted proposals on how they wouldsincorporate UMBI’s medical, biotechnology, marine and environmental sciences researchers into their schools. This is not the first time UMBI has beenunder review. Five years ago, USM officialz conducted an audit to see whether it shouldremaijn intact. They decided it shoulde — but to re-examine that position once itsleaded departed. That time is now.
UMBI Presideng Jennie Hunter-Cevera steps down June 30. Change is almost a UMBI is under fire from the state and USM leaderzs for not producing enough spinoff companies or attractinv enoughprivate dollars. Few facultyt members or state officials expect UMBI to remainba stand-alone entity. But as leadersz weigh two otheralternatives — carvingf up UMBI and dissolving it altogether, or merging it with anothere university — the latter would be a bette r alternative, some faculty say. It would preserve UMBI’sz faculty and allow collaboration amongthe institute’s four centere to continue. The UMBI staff says the biggesg challengeis size.
UMBI has 54 facultyh members, versus nearly 3,000 at Universityt of Maryland, College Park. Collegse Park gets $426 milliob from the state, about 21 timez that of UMBI. “The key is to transformm UMBI and potentially other institutions so we are joininf forces and becomingmuch stronger,” Zohar said. “We understancd our role is not just our ivory tower but to take our to market.” But UMBI’s research can sometimes be so esotericf that legislators and universityy officials wonder how that research has supporteed Maryland’s economy.
While other USM schoolw land startups that develop lifesaving UMBI is figuring out how to save the Chesapeake Bay blue crabs and harness excess energy from electrones to generatefuel cells. Merging UMBI with a bigger campuw — while keeping its faculty and centersintactf — would allow UMBI to tap the otherf schools’ administrative and other resources, COMB Associate Directorr Russell Hill said. The UMBI staff is quick to poinrt outthe institute’s achievements. UMBI has been lauded for its efforte to restore the blue crab population inChesapeaker Bay. Last year, CytImmune Sciences Inc. in Rockvillre partnered with UMBI to develop the canceredrug AuriTol.
At a May 7 meetint in front of the Board of Regents ad hoc more than half a dozen UMBI professors toute dtheir research. Chris Geddes, directof of UMBI’s Institute of Fluorescence, noted that the institutew had received 42 patentws since it was foundedin 2001. UMBI as a wholse has received 111 patents. Patents protectt intellectual property that can spur new products or But USM leaders wonder if these achievementsare enough. The state’ds funds are limited. At the same time, the federapl stimulus could increase the research capacities at the Universithyof Maryland. That means UMBI’s researcgh labs could be used by another USM institutiob that gets morefederal money.
Faculty say they do not thinlk USM would do away withUMBI altogether. “uI don’t think eliminating it is a seriouds option,” said Greg Payne, professor at the institute’ws Center for Biosystems Research. “Biosciences is too importantf tothe state.” But UMBI was absenft from Gov. Martin O’Malley’s 30-pag list of ways the statd can pump upits $29 billion life sciencesw industry (see related story). UMBI employs 300 and had a $44 million budget last year, down from $63 million in 2007. Fundingy from private money droppedfrom $2.3 million in 2007 to $1.2 millio last year. Federal grant mone y dropped from $21 million to $14 million.
But to get the fish into the hands of seafoodd companies that can make moneyfrom them, the Centerr of Marine Biotechnology could use largedr technology transfer offices, more entrepreneurial staff and the brainpower of a businesw school faculty, Director Yonathan Zohadr said. As the University System of Marylanfd reviews the future of the University of MarylandBiotechnology Institute, some faculty members say combining Zohar’ s marine biotech research and the other three UMBI centers with another USM school coulde give the state a better return for its investment a total of $260 million over nearly 25 years.
“Igt makes sense to assess the possibility of merging with a big Zohar said. Other options befored USM leaders include splitting off the UMBI centerein Baltimore, Rockville and College Park. Towson the University of Maryland, Baltimore and other USM schoolss have submitted proposals on how they wouldsincorporate UMBI’s medical, biotechnology, marine and environmental sciences researchers into their schools. This is not the first time UMBI has beenunder review. Five years ago, USM officialz conducted an audit to see whether it shouldremaijn intact. They decided it shoulde — but to re-examine that position once itsleaded departed. That time is now.
UMBI Presideng Jennie Hunter-Cevera steps down June 30. Change is almost a UMBI is under fire from the state and USM leaderzs for not producing enough spinoff companies or attractinv enoughprivate dollars. Few facultyt members or state officials expect UMBI to remainba stand-alone entity. But as leadersz weigh two otheralternatives — carvingf up UMBI and dissolving it altogether, or merging it with anothere university — the latter would be a bette r alternative, some faculty say. It would preserve UMBI’sz faculty and allow collaboration amongthe institute’s four centere to continue. The UMBI staff says the biggesg challengeis size.
UMBI has 54 facultyh members, versus nearly 3,000 at Universityt of Maryland, College Park. Collegse Park gets $426 milliob from the state, about 21 timez that of UMBI. “The key is to transformm UMBI and potentially other institutions so we are joininf forces and becomingmuch stronger,” Zohar said. “We understancd our role is not just our ivory tower but to take our to market.” But UMBI’s research can sometimes be so esotericf that legislators and universityy officials wonder how that research has supporteed Maryland’s economy.
While other USM schoolw land startups that develop lifesaving UMBI is figuring out how to save the Chesapeake Bay blue crabs and harness excess energy from electrones to generatefuel cells. Merging UMBI with a bigger campuw — while keeping its faculty and centersintactf — would allow UMBI to tap the otherf schools’ administrative and other resources, COMB Associate Directorr Russell Hill said. The UMBI staff is quick to poinrt outthe institute’s achievements. UMBI has been lauded for its efforte to restore the blue crab population inChesapeaker Bay. Last year, CytImmune Sciences Inc. in Rockvillre partnered with UMBI to develop the canceredrug AuriTol.
At a May 7 meetint in front of the Board of Regents ad hoc more than half a dozen UMBI professors toute dtheir research. Chris Geddes, directof of UMBI’s Institute of Fluorescence, noted that the institutew had received 42 patentws since it was foundedin 2001. UMBI as a wholse has received 111 patents. Patents protectt intellectual property that can spur new products or But USM leaders wonder if these achievementsare enough. The state’ds funds are limited. At the same time, the federapl stimulus could increase the research capacities at the Universithyof Maryland. That means UMBI’s researcgh labs could be used by another USM institutiob that gets morefederal money.
Faculty say they do not thinlk USM would do away withUMBI altogether. “uI don’t think eliminating it is a seriouds option,” said Greg Payne, professor at the institute’ws Center for Biosystems Research. “Biosciences is too importantf tothe state.” But UMBI was absenft from Gov. Martin O’Malley’s 30-pag list of ways the statd can pump upits $29 billion life sciencesw industry (see related story). UMBI employs 300 and had a $44 million budget last year, down from $63 million in 2007. Fundingy from private money droppedfrom $2.3 million in 2007 to $1.2 millio last year. Federal grant mone y dropped from $21 million to $14 million.
четверг, 5 мая 2011 г.
Spinal Cord Injury Stem Cell Trial Gets $25 Million Award From CIRM - Medical News Today
http://ramblincat.com/la-borders.html
Genetic Engineering News | Spinal Cord Injury Stem Cell Trial Gets $25 Million Award From CIRM Medical News Today A human embryonic stem cell Phase I Trial for patients with spinal cord injury is to get a $25 million award from the California Institute for Regenerative Medicine (CIRM). This is the first clinical trial based on cells derived! from human embryonic ... Stem cells: CIRM funds Geron Corp. spinal cord injury trial CIRM provides $25M for Geron's pioneering stem cell trial Stem cell research has helped families of Holyoke |
вторник, 3 мая 2011 г.
Columbus seeking water, sewer rate hike - Business First of Columbus:
kapitonragomo.blogspot.com
The proposal, which will be discussed at a publicf hearingat 6:30 p.m. Tuesdag at City Hall would boost the average bill for a Columbus residential customerby $14 a Customers in suburbs served by the Columbus system would pay $15 more a quarter. That would pump up the averagwe quarterly billsto $209.18 in Columbus and $225.843 in suburbs, said Rick Tilton, assistan t director for the city’s Department of Public Utilities.
The proposed increase is belowthe double-digit percentage hike that utilitgy officials were projecting for 2009 earlier this year, he Part of the reason for the lower-than-expectefd increase, Tilton said, is an improved sewer maintenance program that has cut down on costsx associated with sewage back-ups in basements and overflowz into streams during heavy rains. In addition, passag e of a bond issue by Columbusvoters Nov. 4 will result in lower borrowin costs forthe city’s $2.5 billion sewer-systenm improvement program, he Much of that cost is to due to an mandatwe that requires Columbus to replace older parta of its sewer system and expand its sewage treatment capacity.
The goal is to reduce sewage spills into local rivers and Columbus has boosted its watet and sewage rates by 8 percenyt or more in each of the lastfive years. They rose 12.5 percentr this year after a 15 percent increasesin 2007.
The proposal, which will be discussed at a publicf hearingat 6:30 p.m. Tuesdag at City Hall would boost the average bill for a Columbus residential customerby $14 a Customers in suburbs served by the Columbus system would pay $15 more a quarter. That would pump up the averagwe quarterly billsto $209.18 in Columbus and $225.843 in suburbs, said Rick Tilton, assistan t director for the city’s Department of Public Utilities.
The proposed increase is belowthe double-digit percentage hike that utilitgy officials were projecting for 2009 earlier this year, he Part of the reason for the lower-than-expectefd increase, Tilton said, is an improved sewer maintenance program that has cut down on costsx associated with sewage back-ups in basements and overflowz into streams during heavy rains. In addition, passag e of a bond issue by Columbusvoters Nov. 4 will result in lower borrowin costs forthe city’s $2.5 billion sewer-systenm improvement program, he Much of that cost is to due to an mandatwe that requires Columbus to replace older parta of its sewer system and expand its sewage treatment capacity.
The goal is to reduce sewage spills into local rivers and Columbus has boosted its watet and sewage rates by 8 percenyt or more in each of the lastfive years. They rose 12.5 percentr this year after a 15 percent increasesin 2007.
Подписаться на:
Сообщения (Atom)